RVNC News
Archived Headlines
- Foam-focused acne fighter Foamix Pharmaceuticals sets terms for $65 million IPO 09/03/14
- Acne biotech Foamix Pharmaceuticals files for a $75 million IPO 08/13/14
- Aesthetic medical device maker Ulthera formally withdraws IPO; acquired by Merz for $600 million 07/22/14
- US IPO Recap: Revance jumps 68% in ten-IPO week 02/10/14
- Revance Therapeutics prices upsized IPO at $16, at the high end of the range 02/06/14
See more
Botox for the masses: Evolus files for a $75 million IPO
Evolus, which is preparing to launch a biosimilar version of botox, filed on Tuesday with the SEC to raise up to $75 million in an initial public offering. The Irvine, CA-based company was founded in 2012 and plans to list on the Nasdaq under the symbol...read more
Botox biotech Anterios postpones $51 million IPO
Anterios, which is developing a topical formulation of botulinum toxin, postponed its IPO on Friday. The New York, NY-based company had planned to raise $51 million by offering 3.9 million shares at a price range of $12 to $14. At the midpoint of the...read more
Botox biotech Anterios files for a $58 million IPO
Anterios, which is developing a topical formulation of botulinum toxin, filed on Tuesday with the SEC to raise up to $58 million in an initial public offering. Revance Therapeutics (RVNC), which is also developing a topical formulation of botulinum...read more
The LIPO IPO: Neothetics files to raise $63 million to fight fat with an asthma drug
Neothetics, a biotech targeting fat reduction with an injectable formulation of an approved asthma drug, filed on Friday with the SEC to raise up to $63 million in an initial public offering. Business The company has completed Phase 2 trials for...read more